United States ex rel. Thorpe v. GlaxoSmithKline PLC

89 F. Supp. 3d 231, 2015 U.S. Dist. LEXIS 27757, 2015 WL 996433
CourtDistrict Court, D. Massachusetts
DecidedMarch 6, 2015
DocketCivil Action No. 03-10641-RWZ
StatusPublished
Cited by1 cases

This text of 89 F. Supp. 3d 231 (United States ex rel. Thorpe v. GlaxoSmithKline PLC) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States ex rel. Thorpe v. GlaxoSmithKline PLC, 89 F. Supp. 3d 231, 2015 U.S. Dist. LEXIS 27757, 2015 WL 996433 (D. Mass. 2015).

Opinion

MEMORANDUM OF DECISION

ZOBEL, District Judge.

Plaintiff Blair Hamrick brought this suit under the anti-retaliation provision of the False Claims Act (“FCA”), 31 U.S.C. § 3730(h), for his termination from employment at the defendant GlaxoSmithK-line (“GSK”). GSK has moved for summary judgment.

I. Background

Plaintiff spills much ink recounting his ■ long and difficult history at the company, including various perceived and actual slights and mistreatment, all of which is irrelevant to the present cause of action. The essential facts for this opinion follow, taken from the undisputed record.

Blair Hamrick began work at GSK as a pharmaceutical sales representative in Colorado in 1997. On January 30, 2002, plaintiff met with a GSK Compliance Officer to discuss plaintiffs allegations regarding off-label drug presentations sponsored by GSK.

On October 19, 2003, Hamrick was cited for driving under the influence of alcohol (“DUI”). On October 24, 2003, he voluntarily took a medical leave of absence because of anxiety and symptoms of post-traumatic stress disorder. On January 22, 2004, Hamrick pled guilty to driving while alcohol impaired (“DWAI”) in connection with the October 2003 DUI citation.

Plaintiff returned to work on January 27, 2004, in his then current position as Senior Executive Sales Representative. On January 29, he had a call with Gail Fletcher and Claudia Pattison, managers in the Human Resources Department (“HR”), concerning his allegations of off-label drug presentations. On February 12, he met with Pattison to continue discussing his concerns regarding off-label drug presentations.

During the February 12, 2004, meeting with Pattison, plaintiff expressed anger towards his co-worker Peter Copeland, saying that he “would never do this, but ... [Peter] is lucky I don’t rip his trachea out of his throat.” Pattison was particularly concerned about this violent ideation, as she was aware Hamrick in fact carried a gun.

On March 16, 2004, Hamrick attended a GSK conference in Dallas, Texas. During the conference, while under the influence of prescription anti-anxiety medications and alcohol, he made several threats of violence against GSK managers. Three GSK employees reported plaintiff stating, and plaintiff does not dispute stating, the following:

• “I hate this company. I’ve hated it since the merger. I’d like to take a gun and shoot some people.”
[233]*233• “[I]f there’s one thing I need from a ' 30-day psych leave, it’s another leave. You don’t understand, I’m obsessed with these thoughts. Let me give you an example. I’ve been having these dreams where I am in a wrestling match with Jerry [Nelson] and Pat [Keith] and I hit Jerry in' the eye and his eye pops out and I' hit Pat and crush his windpipe.”
• “I’d like to kill [Jerry Nelson]. No, I wouldn’t have any remorse whatsoever. I’d like to kill him.”
• “I want to kill that fucker [Pat Keith].”
• Hamrick was also reported to have said he was having dreams of jamming his thumbs into Pat Keith’s eyes and ripping the eyeballs out.
GSK’s “Violence-Free Workplace Policy” states that
“[a]ny person who threatens, [or] exhibits threatening behavior ... on [GSK] property or at [GSK] sponsored events will be removed from the premises immediately, and will remain off premises pending the outcome of an investigation. A timely investigation will be made concerning the allegations. Should the investigation substantiate that violations of this policy have occurred, [GSK] will initiate a decisive and appropriate response.”

Pursuant to that policy, Hamrick was immediately placed on administrative leave with pay pending an investigation into his statements in Dallas.

During this administrative leave, GSK became aware of Hamrick’s DUI citation and DWAI conviction through its annual motor vehicle record check of those who, like Hamrick, possessed company-owned vehicles. He had not reported either occurrence to GSK, in violation of company policy.

In light of the reason for Hamrick’s leave, GSK requested he undergo a fitness for duty (“FFD”) evaluation on April 2, 2014, with an understanding by Hamrick that refusal to undergo the FFD would be grounds for termination. In response to this request, Hamrick provided a letter from his own psychiatrist, Dr. Crandall, stating her opinion that Hamrick is capable of performing his job responsibilities at GSK. Doctor Crandall had not evaluated Hamrick since his violent threats.

On April 19, plaintiff sent GSK a request for severance. On June 2, GSK responded with a counter-offer, and on June 6, plaintiff rejected the counter-offer and stated that he no longer wished to resign.

GSK’s then Director of HR, Bill Reedy, scheduled a meeting with Hamrick on June 23 to discuss Hamrick’s allegations about off-label marketing and his violations of policy (his driving offense and his threats of violence). Hamrick was informed that, per company policy, he could be accompanied by his attorney when GSK’s attorneys were present during the meeting, but not during the HR portion of the meeting when no GSK attorneys would be present, which would cover his conduct issues.

On June 22, Hamrick’s attorney, Keith Cross, informed Mr. Reedy that Hamrick would not meet with GSK without his attorney present. Due to this refusal, the meeting was cancelled. On September 1, GSK’s outside counsel, Geoffrey Hobart, sent Cross a letter concerning Hamrick’s refusal to meet with GSK, and explained that Hamrick was bound by GSK’s Code of Conduct, and that “failure to fully cooperate with an investigation of an incident that occurs in the workplace” would be a further violation of company policy, potentially subjecting Mr. Hamrick to termination.

[234]*234There followed a series of communications between counsel for the parties. On September 3, Cross responded, setting multiple conditions and terms of any meeting between Hamrick and GSK. On September 20, Hobart reiterated the company’s request for an investigatory meeting and again stated that Cross could attend the portions of the meeting regarding off-label marketing but not those portions solely concerning the HR investigation of Hamrick’s threats and unreported driving infraction. On September 24, Cross informed Hobart that plaintiff would not meet with GSK. On October 13, GSK informed Hamrick, through his attorney, that he had been terminated due to his threatening and violent statements regarding GSK employees, his failure to report his DUI citation and DWAI conviction, and his refusal to cooperate with GSK’s investigation.

II. Standard of Review

Summary judgment is appropriate when the moving party shows that there is no genuine dispute of material fact and the movant is entitled to judgment as a matter of law. Fed.R.Civ.P. 56(c). In considering whether or not a genuine issue of material fact exists, the court “must view the evidence in the light most favorable to the opposing party.” Tolan v. Cotton, — U.S. -, 134 S.Ct. 1861, 1866, 188 L.Ed.2d 895 (2014).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Persson v. Boston University
D. Massachusetts, 2019

Cite This Page — Counsel Stack

Bluebook (online)
89 F. Supp. 3d 231, 2015 U.S. Dist. LEXIS 27757, 2015 WL 996433, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-thorpe-v-glaxosmithkline-plc-mad-2015.